Literature DB >> 20338618

Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.

Kjersti Flatmark1, Ben Davidson, Alexandr Kristian, Helene Tuft Stavnes, Mette Førsund, Wenche Reed.   

Abstract

Peritoneal surface malignancies are characterized by the propensity for tumor growth on peritoneal surfaces without development of extraperitoneal metastases, but the molecular basis for this phenomenon is incompletely understood. Five human tumors and corresponding orthotopic animal models of human pseudomyxoma peritonei and peritoneal mucinous carcinomatosis from colorectal carcinoma were extensively characterized by immunohistochemical analysis of molecular markers of tissue differentiation (carcinoembryonal antigen, CK20, CK7, and vimentin), proliferation and metastasis (Ki-67, vascular endothelial growth factor, and S100A4), mucins (MUC1, MUC2, MUC4, MUC5AC), and adhesion molecules (E-cadherin, N-cadherin, P-cadherin, claudin 1, claudin 3, and claudin 4). Macro- and microscopic growth patterns of implanted human tissues were preserved through passages in the animals, as were with few exception immunohistochemical staining profiles, supporting the relevance of the models as tools for studying the human disease. Tissue differentiation marker expression was in accordance with previously published results and high Ki-67 score confirmed high proliferative capacity, whereas absence of metastatic capacity was supported by low expression levels of the studied metastasis markers. These mucinous tumors expressed high levels of MUC2 and MUC4, whereas MUC1 was not expressed and MUC5AC expression was variable. Similarly, specific adhesion molecules from the cadherin and claudin families were shown to be of relevance in the investigated samples. The results indicate that mucinous peritoneal surface malignancies of intestinal origin are characterized by the presence of specific molecular markers and represent a step toward understanding the complexity of this intriguing phenotypic entity. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20338618     DOI: 10.1016/j.humpath.2009.12.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

Review 1.  Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei.

Authors:  Veena Ramaswamy
Journal:  Indian J Surg Oncol       Date:  2016-03-19

2.  Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines.

Authors:  Darren L Roberts; Sarah T O'Dwyer; Peter L Stern; Andrew G Renehan
Journal:  Oncotarget       Date:  2015-05-10

3.  Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models.

Authors:  Karianne Giller Fleten; Christin Lund-Andersen; Stein Waagene; Torveig Weum Abrahamsen; Yrr Mørch; Kjetil Boye; Annette Torgunrud; Kjersti Flatmark
Journal:  Transl Oncol       Date:  2020-05-21       Impact factor: 4.243

Review 4.  Role of Epithelial-Mesenchymal Plasticity in Pseudomyxoma Peritonei: Implications for Locoregional Treatments.

Authors:  Maria Luisa Calabrò; Nayana Lazzari; Giulia Rigotto; Marco Tonello; Antonio Sommariva
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

Review 5.  Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; David Lawson Morris
Journal:  Orphanet J Rare Dis       Date:  2014-05-05       Impact factor: 4.123

6.  Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.

Authors:  Murali R Kuracha; Peter Thomas; Brian W Loggie; Venkatesh Govindarajan
Journal:  Cancer Med       Date:  2016-02-02       Impact factor: 4.452

7.  MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer.

Authors:  Yvonne Andersson; Synne Ihler Haavardtun; Ben Davidson; Anne Dørum; Karianne G Fleten; Øystein Fodstad; Kjersti Flatmark
Journal:  Oncotarget       Date:  2017-06-27

8.  Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei.

Authors:  Olaf Sørensen; Anders Mikal Andersen; Stein Gunnar Larsen; Karl-Erik Giercksky; Kjersti Flatmark
Journal:  Clin Exp Metastasis       Date:  2019-09-20       Impact factor: 5.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.